Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

This AJMC^® Profiles in Care provides an in-depth look into the results of the innovative outcomes-based agreement between Boehringer Ingelheim and Highmark Inc that focused on total cost of care for patients with type 2 diabetes and cardiovascular disease. An overview of the results, as well as valuable insights from experts from Boehringer Ingelheim and Highmark, are included.

Download PDF: Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Outcomes-Based Agreements Give New Insight for Treatment of Diabetes and Cardiovascular Disease

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Stem Cell Engineering Reveals New Clues to Rebuilding Beta Cells

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants

Dermatology Practices Absorb Rising Prior Authorization Costs

Dry Eye Disease Is More Than "Dry Eyes": Experts Explain the 2 Types

Multidisciplinary Teams Improve Biomarker Testing and Lung Cancer Care: Urs Weber, MD